Vuse Sales Halt Offset by Cost Controls; BAT Malaysia Reports $17 Million Net Profit in H1

Jul.29.2025
Vuse Sales Halt Offset by Cost Controls; BAT Malaysia Reports $17 Million Net Profit in H1
In the first half of fiscal year 2025, British American Tobacco Malaysia reported a net profit of $17.07 million. The company attributed the gains to improved cost efficiency and a more focused product portfolio following the discontinuation of its Vuse e-cigarette operations in the country.

Key points:

 

·British American Tobacco Malaysia is focusing on the traditional cigarette market in Malaysia and has achieved significant performance growth. 

 

·In the second quarter, the company's operating profit increased by 38.5% to reach 78 million Malaysian Ringgit (approximately $17.9 million). The Dunhill brand continues to hold a leading position in Malaysia. 

 

·A decrease in black market tobacco trading has had a positive impact on the company's performance.

 


 

【2Firsts News Flash】According to The Star's report on July 28th, British American Tobacco Malaysia Bhd has seen success in its traditional cigarette business, particularly with its flagship brand, Dunhill. The company's performance in the second quarter showed improvement compared to the same period in 2024.

 

According to the group, the decision to stop operations of the e-cigarette brand Vuse has led to more efficient cost management, a more concentrated product portfolio, and an operating profit increase of 38.5% compared to the same period last year, reaching 78 million ringgit (approximately 17.9 million).

 

In terms of revenue, British American Tobacco saw a slight decrease in the second quarter of the 2025 fiscal year, reaching RM6.2475 billion (approximately $1.44 billion), compared to RM6.4046 billion (approximately $1.47 billion) during the same period in 2024.

 

In the first half of the 2025 fiscal year, British American Tobacco reported a net profit of 74.22 million ringgit (approximately $17.07 million), compared to 66.27 million ringgit (approximately $15.24 million) in the same period in the 2024 fiscal year. During this time, revenue decreased from 1.05 billion ringgit (approximately $242 million) in 2024 to 946.74 million ringgit (approximately $218 million).

 

Nedal Salem, the Managing Director of British American Tobacco Malaysia, stated in a press release:

 

"Our second quarter performance demonstrated the resilience of our traditional cigarette products, indicating that we are heading in the right strategic direction even in a fiercely competitive market environment. Dunhill continues to maintain its leading position in Malaysia and has gained further momentum this quarter."

 

In addition, he pointed out that compared to the previous quarter, illegal tobacco trading in the second quarter of the 2025 fiscal year also decreased by 0.4 percentage points to 54.4%.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

EU Launches Online Feedback as TPD Revision Enters New Milestone
EU Launches Online Feedback as TPD Revision Enters New Milestone
The European Commission has opened an online call for evidence on revising EU tobacco products and advertising rules, marking a new phase in the TPD/TAD review. Policy options may cover novel products, flavours, packaging, digital marketing and advertising. A 2Firsts review of 855 early submissions shows rapid engagement and recurring debate over differentiated regulation, harm reduction, youth protection, illicit trade and economic impact.
Special Report
May.21
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 2.988 billion, up 4.57% year on year, while net profit attributable to shareholders turned to a loss of RMB 346 million. In the first quarter of 2026, revenue rose 58.13% year on year to RMB 1.005 billion, but attributable net profit fell 45.16% to RMB 36.5349 million. The company said both revenue and cost growth were related to the expansion of its new tobacco business.
Apr.28 by 2FIRSTS.ai
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai